Showing results (1101-1110 of 1,119) with videos related to

Sort By:
Pageof 112
The Lancet. Infectious Diseases|September 10, 2022
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trialMehreen S Datoo, Hamtandi Magloire Natama, Athanase Somé, et al.
Cancers|May 14, 2022
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA RegistryJorge Labrador, David Martínez-Cuadrón, Adolfo de la Fuente, et al.
EFSA Journal. European Food Safety Authority|February 18, 2026
Safety and efficacy of a feed additive consisting of molybdenum in form of a chelate with ethylenediaminetetraacetic acid (EDTA) for honeybees and bumblebees (SATT Paris Saclay), Roberto Edoardo Villa, Giovanna Azimonti, et al.
The Lancet. Microbe|January 13, 2025
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection studyNavin Venkatraman, Daniel Silman, Duncan Bellamy, et al.
International Journal of Molecular Sciences|April 20, 2017
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational StudyAntonio M Almeida, Thomas Prebet, Raphael Itzykson, et al.
EFSA Journal. European Food Safety Authority|November 1, 2023
Safety and efficacy of the feed additive consisting of <i>Enterococcus lactis</i>NCIMB 10415 (Cylactin®) for all poultry for fattening or reared for laying/breeding and ornamental birds, all Suidae, calves and other ruminant species for fattening or rearing (DSM Nutritional products Ltd), Vasileios Bampidis, Giovanna Azimonti, et al.
Frontiers in Immunology|May 15, 2026
Clinical, laboratory and genetic characteristics of VEXAS syndrome: a study on behalf of GESMDMarta Fonseca-Santos, Borja Puertas, Javier Arzuaga-Méndez, et al.
Cancers|June 2, 2021
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical TrialRosa Ayala, Inmaculada Rapado, Esther Onecha, et al.
Cancer|February 24, 2021
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemiaSusana Vives, David Martínez-Cuadrón, Juan Bergua Burgues, et al.
British Journal of Haematology|July 16, 2025
Insights into the clinical, platelet and genetic landscape of inherited thrombocytopenia with malignancy riskAna Marín-Quílez, Ana Sánchez-Fuentes, Ana Zamora-Cánovas, et al.
Pageof 112